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(R/S)-1-(4-Fluorophenyl)-2-(methylamino)propan-1-one, also known as flephedrone or 4-
FMC, has emerged in recent years as a recreational psychostimulant. Its synthesis was first 
published in 1952 in order to explore the potential for antithyroidal, antibacterial and 
bacteriostatic properties.  Publications about the detection of 4-FMC obtained from Internet 
sources and test purchases started to appear from 2009 onwards. The first official notification 
submitted to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) by 
a European member state was 2008. Since then, it has been detected across the globe as a 
reflection of modern forms of trade within a globalised world. As was the case with many 
other emerging substances with psychoactive properties, commonly used terms include "legal 
highs", "bath salts" or "new psychoactive substances" (NPS) in the attempt to highlight the 
fact that many, if not most, did not originally fall under any legislative control and that 
detailed data on both pre-clinical and clinical levels were normally less well explored.  
 
The amount of research data on 4-FMC is comparatively small in comparison with other 
cathinones such as 4-methyl-N-methylcathinone (mephedrone) or 3,4-
methylenedioxypyrolvalerone (MDPV) but the currently available data suggest that the 
psychoactive and behavioural profile of 4-FMC, for example demonstrated by drug 
discrimination and in-vitro studies, show similarities to psychomotor stimulants such as 
cocaine, methcathinone and methamphetamine although it appears that it be less potent. It has 
been demonstrated that key targets of 4-FMC include monoamine transporters and that it 
functions as a catecholamine-selective substrate-type releaser of dopamine and 
norepinephrine. 
 
While 4-FMC was a low potency partial agonist at the 5-HT1A receptor, it was found to be an 
antagonist with very low potency at 5-HT2A and 5-HT2C receptors. 4-FMC was observed to 
act primarily as a substrate at the human dopamine (hDAT) and human norepinephrine 
transporter (hNET), with the latter being more pronounced than methamphetamine. In 
addition, it was observed to display appreciable affinity to the hα1A adrenoceptor and rat trace 
amine-associated receptor 1.  
 
The ability to induce DA release similar to methamphetamine-type substances known to act as 
hDAT substrates makes it likely that 4-FMC may show abuse potential. It seems conceivable 
that, especially at high dosage levels,  extensive release of NE in combination with hα1A 




A. International Nonproprietary Name (INN) 
  -- 
B.  Chemical Abstract Service (CAS) Registry Number 
  447-40-5 (free base) 
  7589-35-7 (hydrochloride salt) 
  1419921-83-7 (1-(4-fluorophenyl-1,2,3,4,5,6-13C6) free base) 
  1286101-71-0 (N-CD3 hydrochloride salt) 




  1388142-25-3 (R-enantiomer free base) 
  1388142-26-4 (S-enantiomer free base) 
 
C. Other Names 
 4-FMC, flephedrone, 4-fluoromethcathinone, 4-flephedrone, 4-fluoro-N- 
   methylcathinone, p-fluoromethcathinone, p-fluoro-N-methylcathinone 
D. Trade Names 
  -- 
E.  Street Names 
  4-FMC, flephedrone. 
F. Physical properties 
  4-FMC HCl is a white crystalline powder. 
G. WHO Review History 
4 - FMC was not previously pre-reviewed or critically reviewed. A direct 
critical review is proposed based on information brought to WHO’s attention 
that 4 - FMC is clandestinely manufactured, of especially serious risk to public 
health and society, and of no recognized therapeutic use by any party. 
Preliminary data collected from literature and different countries indicated that 
this substance may cause substantial harm and that it has no medical use.  
 
2.   Chemistry 
A.  Chemical Name 
IUPAC Name: (R/S)-1-(4-Fluorophenyl)-2-(methylamino)propan-1-one 
   
CA Index Name:    
(R/S)-1-(4-Fluorophenyl)-2-(methylamino)-1-propanone 
 




Note: Asterisk (*) refers to a chiral centre 
 
 Molecular Formula: C10H12FNO (base) 
Molecular Weight: 181.21 g/mol    




Boiling point: --   
Fusion point: --  
C.  Stereoisomers 
The presence of a chiral centre at the α-carbon of the side chain gives rise to the 
enantiomeric pair of (S)-4-FMC and (R)-4-FMC, respectively. Currently, it appears 
that data about their optical rotation or potential to display distinguishable 
pharmacological properties have not been published. 4-FMC is most likely to be 
available as the racemic mixture. 
D.  Synthesis 
The first synthesis of 4-FMC has been published in 1952 by Kraft and Dengel 
following the scheme shown below.1 This key procedure includes  the α-bromination 
(step i) of the propan-1-one precursor (a) and formation of the 2-bromoppropan-1-one 
intermediate (b). Reaction with N-methylamine (step ii) gives 4-FMC (c) which may 
then be converted into a range of salts. One of several alternatives may include the 




E. Chemical description 
4-FMC, i.e. (R/S)-1-(4-fluorophenyl)-2-(methylamino)propan-1-one, contains a 2-
amino-1-phenylpropan-1-one nucleus which forms the structural basis for many 
cathinone-based substances that are known to interact with a range of targets found, 
for example, in the central nervous system.  
F.  Chemical properties 
4-FMC HCl is a water-soluble white crystalline powder. During preparation of the 
hydrochloride salt, a blue and brown colour formation was temporarily observed.1  
 
G.  Chemical identification 
4-FMC, as well as many other cathinones, has been repeatedly characterized in recent 
years. The first report that described its identification in a sample obtained from an 
internet supplier was published in 2009 by Archer. Confirmation was obtained from 
synthesis and analytical characterisation by gas chromatography-mass spectrometry 
(GC-MS), attenuated total reflectance (ATR) Fourier transform (FT) infrared (IR) 
spectroscopy and 1H, 13C and 19F nuclear magnetic resonance spectroscopy (NMR).2 
In addition to similar data, the first GC chemical ionisation mass spectrum was 
published in 2010.3 4-FMC was reported to give a purple (ninhydrin reagent) or 
orange colour when using the Dragendorff's reagent (+ 10% H2SO4) and a full scan 
ultraviolet (UV) spectrum was provided (amongst similar data mentioned above) in a 
2010 forensic report from Tokyo on test purchases in 2009.4 Electrospray ionisation 




been described for the detection of 4-FMC and other cathinones. Under certain 
conditions, examples of cross-reactivity have been described.7,8  
3.  Ease of convertibility into controlled substances 
 




Similar to other well-established psychostimulants, a key principle involved in the 
molecular mechanisms of 4-FMC is the interaction with transport proteins that lead to 
the elevation of extracellular neurotransmitter levels, most notably, dopamine (DA), 
norepinephrine (noradrenaline, NE) and serotonin (5-HT), respectively. 
 
However, an  important question relates to the ability of a psychostimulant to act as a 
monoamine re-uptake inhibitor (e.g.  cocaine-like) or as a substrate-type releaser 
(amphetamine-like). In the latter case, this  may be achieved by transporter-mediated 
translocation of the drug into the cytoplasm in exchange of the monoamine which may 
be exacerbated by additional release from vesicular storage, thus leading to increasing 
monoamine availability for further release.9 The key targets of interest normally 
include the evaluation of drug action at the dopamine (DAT), norepinephrine (NET) 
and serotonin (SERT) transporters. Recently published research demonstrated that 4-
FMC acted as a substrate, rather than an uptake blocker which is a property also 
shared with cathinone, methcathinone, mephedrone and methylone, respectively.10-12 
 
4.1.  Pharmacodynamics 
 
In-vitro pharmacology 
Simmler et al.11 found that 4-FMC displayed the ability to inhibit monoamine 
transporters with  IC50 values in the low µM range with ~ 26-fold selectivity to hNET 
(0.246 µM) over hDAT (6.35 µM) in HEK cells (Table 1). In comparison, some of the  
IC50 values observed with other substances were as follows: MDMA (hNET = 0.447, 
hDAT = 17 µM), cocaine (hNET = 0.451, hDAT = 0.768 µM), methamphetamine 
(hNET = 0.064, hDAT = 1.05 µM), respectively. However, 4-FMC seemed somewhat 
catecholamine-selective since the IC50 value for hSERT was > 10 µM. As expected, 
both cocaine and MDMA, were able to show a higher potency for hSERT inhibition 
with IC50 of 2.37 µM and 1.36 µM, respectively.11 Similar selectivities with regards to 
[3H]monoamine uptake inhibition, i.e. hNET > hDAT > hSERT, have been observed by 
Eshleman et al.. The authors also demonstrated that 4-FMC (EC50 = 1.53 µM, Emax = 
194%) released more [3H]NE than methamphetamine (EC50 = 0.128 µM, Emax = 92.7%) 
which showed a closer proximity to methcathinone (EC50 = 0.228 µM, Emax = 149%) 
even though 4-FMC was less potent in comparison. 10    
 
Table 1 shows that 4-FMC acted as a subtype-type dopamine (DA) and norepinephrine 
(NE) releaser (EC50 DAT = 17.8 and 12.5 µM; EC50 NET = 1.53 µM) while high 
concentrations (EC50 > 39 and 33 µM) were required to elicit SERT-mediated [3H]5-HT 
release. This also meant that 4-FMC also showed a preference for catecholamine release 
which differentiated this substance from other releasers that would show an additional 
5-HT component (e.g. mephedrone and methylone).10-12 Table 1 also summarises the 
key data obtained from additional in-vitro studies  such as receptor binding and 




affinity to the 5-HT2A (Ki = 1.4 µM, [3H]ketanserin and spiperone) and α1A adrenoceptor 
(Ki = 1.52 µM, [3H]prazosin and risperidone). While 4-FMC was a low potency partial 
agonist at the 5-HT1A receptor, it was found to be an antagonist with very low potency 
at the 5-HT2A and 5-HT2C receptors. Direct effects on dopamine receptors were not 
observed.10 Activation of the α1A adrenoceptor, on the other hand, has been associated 
with stimulant-induced vasoconstriction and hyperthermia.11 The fact that 4-FMC was 
observed to act primarily as a hDAT and hNET substrate, with the latter being more 
pronounced than methamphetamine, led to the suggestion that a extensive NE activity 
might contribute not only to cardiotoxic effects but also precipitation of panic attacks 
which appear to be frequently observed in acute intoxications with a number of 
cathinones.10   
 
In-vivo pharmacology 
Currently, it appears that two in-vivo studies have been published on 4-FMC (Table 2). 
Marusich et al.13 have explored a range of cathinone analogs and their impact on a 
number of behavioural measures (locomotor activity, rotorod, functional observational 
battery) in male ICR mice (Table 2). Similar cocaine, MDPV and mephedrone, a steady 
attenuation of initially high levels of activity were observed following intraperitoneal 4-
FMC administration which translated to a rapid on- and offset.13 An important approach 
when evaluating abuse liability may also come from drug discrimination studies in 
animals trained to distinguish a training drug from saline. Gatch et al.14 confirmed that 
4-FMC  showed discriminative stimulus effects in cocaine- and methamphetamine-
trained mice (Table 2). Interestingly, with regards to locomotor activity, 4-FMC initially 
produced depressant effects before stimulant effects were observed which might be 




















































































































































































4.3.  Pharmacokinetics 
 
Detailed studies appear to be unavailable at the time of writing. The case report provide 
by Thornton et al.15 currently offers the only description of 4-FMC levels in serum and 
urine following nasal insufflation of a white powder confirmed to contain a mixture of 
4-FMC, MDPV and caffeine (Table 3). 4-FMC levels detected in serum and urine were 
346 and 257 ng/ml following, according to the patient's recollection, insufflation of 1 g 
of powdered material 30-60 min prior to presentation at the emergency department. 
Powder analysis revealed the presence of 4-FMC (142 µg/mg), MDPV (143 µg/mg) and 
caffeine (102 µg/mg). Studies in animals have shown (Table 2) that the initial phase 
following 4-FMC administration was characterised by depression of locomotor 
activity14 whereas a large, rapid initial increases in locomotor activity has been 




A recently carried out assay for cell membrane integrity measuring adenylate kinase 
release from damaged cells via bioluminescence detection (after 4 h of incubation at 
37°C, drug concentrations 10 and 100 μM) did not reveal any indications for 
cytotoxicity under the conditions used11 and further studies are warranted. Eshleman et 
al. suggested that the serum concentrations found in the Thornton et al. case report15 
(Table 3) might have been sufficient to block DA and NE uptake and elicit NE release10 
which may have been consistent with mild sympathomimetic features mentioned by 
Thornton et al.. It is currently not known how these biofluid levels correspond to 




It appears that the only case report involving 4-FMC was published in 2012 by 
Thornton et al. who describe a patient who presented with psychosis and a mild 
sympathomimetic syndrome (Table 3). Analytical confirmation revealed that the white 
powder consisted of a 4-FMC/MDPV/caffeine mixture and agitation was treated with 
intravenously administered droperidol and lorazepam.15 However, it is impossible to 
separate the individual contribution derived from 4-FMC from MDPV, which is a 
powerful, catecholamine-selective transport inhibitor16 with a known potential to cause 




































Detailed clinical studies in humans are not available in the scientific literature and 
 data on prevalence of 4-FMC use in the general population are not obtainable at this 
stage.  Pre-clinical data currently available show that 4-FMC shows a number of 
features that  are consistently observed with some classical psychostimulants (e.g. 
substrate at hDAT and hNET) or DAT/SERT selectivity profile (methamphetamine-like 
cathinones) (see sections above) which suggests the possibility of abuse liability. For 
example, 4-FMC (EC50 = 17.8 µM) was found to be 45-fold less potent than 
methamphetamine  (EC50 = 0.40 µM) in its ability to induce hDAT-mediated [3H]DA 
release10 which indicated that 4-FMC may be a less potent psychostimulant in humans. 
Animal studies have so far indicated that 4-FMC results in a number of increased 
behavioral activities also observed with classical psychostimulants (see sections above). 
The observation of fast on- and offsets associated with 4-FMC and locomotor activity in 
mice13 could suggest a potential for re-dosing in humans but further studies are required 
to address these issues. Gatch et al., on the other hand, reported initial depression of 
locomotor activity and delayed onset of action.14 Further studies, e.g. self-
























Household surveys that specifically probe for prevalence of 4-FMC do currently not 
appear to be available in the published literature. 
 
Oral dosage levels have been tentatively suggested to range between 15-50 mg 
(threshold) and 150-300+ mg (strong) whereas threshold levels obtained from nasal 
insufflation were suggested to range between 5-25 mg (strong: 75-200 mg). The total 
duration of intoxication may last between 1.5-4 hours (p.o.) or 1-2.5 hours via nasal 
insufflation.18,19 Other reports indicate that dosage levels may range from 100-200 mg 
orally, with an optimal dose of 150mg intranasally, and 150 mg to 350 mg rectally. 
Rectal administration as a gel capsule has also been reported.20  
 






The Drug Enforcement Administration, after reviewing the scientific literature, 3-factor 
analysis, consultation of NFLIS, law enforcement, Customs and Border Protection and 
other sources, confirmed that 4-MEC appeared to be sufficiently prevalent to pose a 




No information available.  





As of 11.03.2014, reports have been received from the European early-warning system 
on new drugs that 4-FMC was encountered in seizures or as a used substance in Italy, 
Germany, Hungary, Poland, Czech Republic, Croatia, Bulgaria, France, Belgium, 




September 2008.20 The Drug Enforcement Administration concluded that prevalence of 
use and distribution of 4-FMC warranted inclusion into Schedule 1 of the Controlled 
Substances Act as part of temporary placement.22  
 
Responses obtained to the UNODC questionnaire on NPS (up to 2012) revealed that 4-
FMC was ranked fifth with regards to numbers of reports (35) received. This was only 
superseded by mephedrone (68 reports), MDPV (61 reports), methylone (53 reports) 
and 4-MEC (38).23 
 









The EMCDDA received confirmation that 4-FMC is controlled in the following 
countries20:  
 
 Bulgaria via amendments to the National Drug Law; came into force on 09 
February 2011 
 Croatia (amendments to the List of drugs, psychotropic substances, plants used to 
produce drugs and substances that can be used in the production of drugs 
(precursors) (OG 19/11) (February 2011) 
 Czech Republic via amendment of the Act n. 167/1998 on addictive substances; 
came into force on 22 April 2011 
 Denmark: 4-FMC added to lists of controlled substances (List B)) 
 Finland (in accordance with section 83 of the Medicines Act (395/1987); Finnish 
Medicines Agency) 
 France: controlled since 27 July 2012 
 Germany (by adoption of the 26th Amending Regulation on Narcotic Drugs, i.e. 26. 
Betäubungsmittelrechts-Änderungsverordnung, BtMÄndV; came into force 26 July 
2012 and permanently placed under schedule II (narcotics eligible for trade but not 
for medical prescription) of the German Narcotics Act (Betäubungsmittelgesetz, 
BtMG)) 
 Hungary (as of 3 April 2012, via generic definition, new Schedule C list, i.e. Annex 
1 of Government Decree 66/2012 (IV. 2.)) 
 Ireland via generic definition, Misuse of Drugs Act 1977 (controlled drugs) (2011, 
S.I. No. 551, 2011) 
 Lithuania via amendment to Republic of Lithuania Law on the Control of Narcotic 
Drugs and Psychotropic Substances 
 Poland (as of 8 June 2011) amendment of the act of law on counteracting drug 
addiction from 15 April 2011 




 Romania (Governmental decision, came into force 15 February 2010) 
 Slovakia (List of hazardous substances in Annex, § 2; came into force on 1 October 
2013) 
 Slovenia (via amendment of Decree on classification of illicit drugs, published on 
22 July 2013 in Official Gazette of RS No. 62/2013; came into force 15 days 
afterwards 
 Sweden (classified as narcotics since 1 October 2010) 
 Turkey (Law on Control of Narcotic Substances no 2313, 22 May 2013) 
 United Kingdom via generic definition under 1971 Misuse of Drugs Act 1971; 
came into force 16 April 2010 
 USA: 4-FMC and nine other cathinones have been placed under temporary control 
(Schedule 1) of the Controlled Substances Act.22  
 Singapore, via generic definition, placed 4-FMC under temporary control (Misuse 
of Drugs (Amendment) Act 2012, No. 30 of 2012) 
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Data were obtained from 72 WHO Member States  (18 AFR, 13 AMR, 5 EMR, 29 EUR, 
3 SEAR, 4 WPR). 
 
A total of 65 Member States answered the questionnaire for 4-fluoromethcathinone 
(flephedrone; 4-FMC). Of these, only 28 respondents (AMR 5, EUR 20, WPR 3 )had 




None reported that 4-FMC was currently authorized or in the process of being 
authorized/registered as a medical product in their country. Four respondents reported that this 
substance was used in medical and scientific research. There was no use stated for 4-FMC in 




Fifteen respondents confirmed that there was recreational/harmful use of 4-FMC. Of these, 
four stated that the common route of administration was oral, six oral, inhaling/sniffing, and 
two oral, injection, inhaling/sniffing. On how 4-FMC was obtained, nine stated this was only 
via trafficking while three mentioned combinations of diversion, trafficking and clandestine 
manufacturing. Thirteen respondents reported on the common formulations of 4-FMC 
available with four reporting powder, seven powder and tablet, one powder and liquid and one 
liquid forms. When asked if 4-FMC was used by any special populations two each stated use 
in general population and in clubs; in clubs only and general population only – one specifies 
youth in general population. In 2012, 18 deaths for all cathinones were reported by one 
respondent as well as 3 emergency room visits in another. Four respondents reported 
withdrawal, tolerance and other adverse effects or medical illnesses caused by 4-FMC. These 
included a variety of symptoms and signs such as hallucinations, delusions, excitability, 
agitation, palpitation and other sympathomimetic effects, circulatory and CNS effects. Please 
also refer report on 4 MEC. 
 
One respondent reports ‘available evidence on the overall public health risks associated with 
the use of synthetic cathinones indicates that 4-MEC, 4-MePPP, a-PVP, butylone, pentedrone, 
pentylone, 4-FMC, 3-FMC, naphyrone, and a-PBP can cause acute health problems leading to 
emergency department admissions, violent behaviors causing harm to self or others, or death. 
For example, individuals have presented at emergency departments following exposure to 
some of these synthetic cathinone substances or products containing them. Some of these 
synthetic cathinone substances have been directly or indirectly implicated in the death of 
individuals. For example, a 24-year-old female died after ingesting two capsules of what she 
believed to be ‘‘Ecstasy’’ but was subsequently confirmed to be a mixture of methylone and 
butylone. In 2011, there were 205 reports related to these 10 substances, and in 2012, there 
were 1,302 reports. From January to November 2013 there were 221 reports (excluding 
naphyrone).  National Forensic Laboratory Information System (NFLIS) registered over 8,000 
reports from state and local forensic laboratories identifying these substances in drug related 
exhibits for the period from January 2010 to November 2013 across 42 states. Specifically, in 




substances. 8 In 2011, there were 800 reports from 32 states related to these substances 
registered in NFLIS, in 2012 there were 5,485 reports from 41 states, and from January to 




Of those with information on this substance 24 reported that 4-FMC was controlled under 
legislation that was intended to regulate its availability - 18 under “controlled substance act”, 
three under “medicines law”, one “temporary ban” and two under “analogue legislation”. 
Four respondents stated that there were challenges with the implementation of this legislation. 
On illicit activities involving 4-FMC, one country reported clandestine manufacture, five 
reported processing into the consumer product, 11 reported trafficking, 2 diversion and 11 
countries an internet market.   
Details on seizures are presented below. 
 
 2011 
(number of respondents) 
2012 
(number of respondents) 
Total number of seizures 247 (10) 41 (9) 
Total quantity seized (kg) 150.79 (5) 42.23 (13) 
Total quantity seized 
(ampoules) 
2 (1)  
Total quantity seized (L)  0.001 (1) 
Total quantity seized 
(tablets/pills) 
1,777 (3) 1,035 (2) 
 
IMPACT OF SCHEDULING 
 
Twenty-four respondents reported that if 4-FMC was placed under international control, they 
would have the laboratory capacity to identify the substance. There is no medical use 
reported.  
 
